home / stock / aim / aim news

AIM News and Press, AIM ImmunoTech Inc. From 04/12/23

Stock Information
Company Name: AIM ImmunoTech Inc.
Stock Symbol: AIM
Market: NYSE
Website: aimimmuno.com
Menu
AIM AIM Quote AIM Short AIM News AIM Articles AIM Message Board
Get AIM Alerts

News, Short Squeeze, Breakout and More Instantly...
AIM - AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINE

AIMIA'S LARGEST SHAREHOLDER REMINDS FELLOW SHAREHOLDERS TO VOTE AGAINST BOARD PRIOR TO PROXY VOTING DEADLINE Canada NewsWire In order to be counted at the annual meeting of shareholders, proxies must be received by 10:30 a.m. (Eastern Daylight Time) on April 14, 2023 ...
AIM - AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

OCALA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseas...

AIM - AIM ImmunoTech Inc. (AIM) Q4 2022 Earnings Call Transcript

2023-04-03 11:24:04 ET AIM ImmunoTech Inc. (AIM) Q4 2022 Earnings Conference Call April 03, 2023, 08:30 AM ET Company Participants Thomas Equels - CEO Chris McAleer - Ph.D. Scientific Officer Conference Call Participants Jason McCarthy - Maxim Ed Woo ...

AIM - AIM ImmunoTech GAAP EPS of -$0.40, revenue of $0.14M

2023-04-03 06:37:57 ET AIM ImmunoTech press release ( NYSE: AIM ): FY GAAP EPS of -$0.40. Revenue of $0.14M (flat Y/Y). For further details see: AIM ImmunoTech GAAP EPS of -$0.40, revenue of $0.14M
AIM - AIM ImmunoTech Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

– Company continues to execute across development pipeline of high-value indications with 12 active clinical programs – Well-positioned to achieve multiple near-term, value-driving milestones – Company to host inaugural conference call and webcast today at 8...

AIM - Notable earnings after Friday's close

2023-03-30 17:35:02 ET AIM , ELBM , VERB For Seeking Alpha's full earnings season calendar, click here . For further details see: Notable earnings after Friday's close

AIM - AIM ImmunoTech Bolsters Board of Directors with Appointment of Pharmaceutical Industry Veteran Nancy K. Bryan, with Deep Commercial, Marketing, Business Development and Corporate Finance Expertise

OCALA, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseas...
AIM - AIM ImmunoTech to Report Full Year 2022 Financial Results on March 31, 2023 and Host Inaugural Quarterly Conference Call and Webcast

OCALA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral disea...

AIM - AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

OCALA, Fla., March 16, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral disea...

AIM - AIMIA REPORTS FOURTH QUARTER 2022 RESULTS

AIMIA REPORTS FOURTH QUARTER 2022 RESULTS Canada NewsWire (All figures in Canadian dollars unless otherwise noted) TORONTO , March 16, 2023 /CNW/ - Aimia Inc. (TSX: AIM) reported its financial results for the three months and twelve months ended De...
Previous 10 Next 10